Akero Therapeutics (AKRO) Stock Price, News & Analysis

Company Overview

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $50.12 to $51.39
• 50-Day Range: $21.87 to $57.56
• 52-Week Range: $17.86 to $58.40
• Volume: 810,688 shs
• Average Volume: 2.12 million shs
• Market Capitalization: $3.53 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $75.86
• Consensus Rating: Buy

Akero Therapeutics Stock Analysis - MarketRank™

Akero Therapeutics scored higher than 91% of companies evaluated by MarketBeat, and ranked 96th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Akero Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Akero Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Akero Therapeutics are expected to decrease in the coming year, from ($3.99) to ($4.52) per share.

Price to Book Value per Share Ratio

Akero Therapeutics has a P/B Ratio of 5.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.20% of the outstanding shares of Akero Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Akero Therapeutics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Akero Therapeutics has recently increased by 8.36%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Akero Therapeutics does not currently pay a dividend.

Dividend Growth

Akero Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.75

Percentage of Shares Shorted

5.20% of the outstanding shares of Akero Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Akero Therapeutics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Akero Therapeutics has recently increased by 8.36%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.78

News Sentiment

Akero Therapeutics has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Akero Therapeutics this week, compared to 8 articles on an average week.

Search Interest

15 people have searched for AKRO on MarketBeat in the last 30 days. This is an increase of 650% compared to the previous 30 days.

MarketBeat Follows

5 people have added Akero Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Akero Therapeutics insiders have bought 5.09% more of their company's stock than they have sold. Specifically, they have bought $9,600,000.00 in company stock and sold $9,134,713.00 in company stock.

Percentage Held by Insiders

Only 7.94% of the stock of Akero Therapeutics is held by insiders.

AKRO Stock Analysis - Frequently Asked Questions

How have AKRO shares performed this year?

Akero Therapeutics' stock was trading at $27.82 at the beginning of the year. Since then, AKRO stock has increased by 81.8% and is now trading at $50.58.
View the best growth stocks for 2025 here.

How were Akero Therapeutics' earnings last quarter?

Akero Therapeutics, Inc. (NASDAQ:AKRO) released its quarterly earnings results on Friday, November, 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.90) by $0.15.

When did Akero Therapeutics IPO?

Akero Therapeutics (AKRO) raised $75 million in an IPO on Thursday, June 20th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI served as the underwriters for the IPO and Roth Capital Partners was co-manager.

Who are Akero Therapeutics' major shareholders?

Top institutional shareholders of Akero Therapeutics include Wellington Management Group LLP (10.57%), RTW Investments LP (9.83%), Janus Henderson Group PLC (8.65%) and Price T Rowe Associates Inc. MD (6.19%). Insiders that own company stock include Skorpios Trust, G Walmsley Graham, Andrew Cheng, Jonathan Young, Timothy Rolph, Seth Loring Harrison, Catriona Yale, William Richard White, Patrick Lamy and Tomas J Heyman.
View institutional ownership trends.

How do I buy shares of Akero Therapeutics?

Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Akero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Akero Therapeutics investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 11/08/2024
• Today: 2/21/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AKRO
• CUSIP: N/A
• CIK: 1744659
• Web: www.akerotx.com
• Phone: (650) 487-6488
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $75.86
• High Stock Price Target: $109.00
• Low Stock Price Target: $38.00
• Potential Upside/Downside: +50.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-151,760,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -32.46%
• Return on Assets: -29.83%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 17.25
• Quick Ratio: 17.25

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.61 per share
• Price / Book: 5.26

Miscellaneous

• Outstanding Shares: 69,799,000
• Free Float: 64,257,000
• Market Cap: $3.53 billion
• Optionable: Optionable
• Beta: -0.11